Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Asheville, NC
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Asheville, NC
Click here to add this to my saved trials
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Chapel Hill, NC
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Charlotte, NC
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Durham, NC
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Raleigh, NC
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Cincinnati, OH
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Cleveland, OH
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Portland, OR
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Germantown, TN
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Germantown, TN
Click here to add this to my saved trials
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Nashville, TN
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Grapevine, TX
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Grapevine, TX
Click here to add this to my saved trials
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Houston, TX
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Plano, TX
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Plano, TX
Click here to add this to my saved trials
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
San Antonio, TX
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Burlington, VT
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Burlington, VT
Click here to add this to my saved trials
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Charlottesville, VA
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Richmond, VA
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Seattle, WA
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Tacoma, WA
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Tacoma, WA
Click here to add this to my saved trials
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Madison, WI
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated:  1/5/2016
mi
from
Adelaide,
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence
Status: Enrolling
Updated: 1/5/2016
mi
from
Adelaide,
Click here to add this to my saved trials
A Pilot Study of Hemin Therapy for Gastroparesis (Diabetes Mellitus)
A Pilot Study of Hemin Therapy for Gastroparesis
Status: Enrolling
Updated:  1/5/2016
The Mayo Clinic
mi
from
Rochester, MN
A Pilot Study of Hemin Therapy for Gastroparesis (Diabetes Mellitus)
A Pilot Study of Hemin Therapy for Gastroparesis
Status: Enrolling
Updated: 1/5/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
Status: Enrolling
Updated:  1/5/2016
Novartis Investigative Site
mi
from
Mobile, AL
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
Status: Enrolling
Updated: 1/5/2016
Novartis Investigative Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
Status: Enrolling
Updated:  1/5/2016
Novartis Investigative Site
mi
from
San Diego, CA
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
Status: Enrolling
Updated: 1/5/2016
Novartis Investigative Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
Status: Enrolling
Updated:  1/5/2016
Novartis Investigative Site
mi
from
San Diego, CA
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
Status: Enrolling
Updated: 1/5/2016
Novartis Investigative Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
Status: Enrolling
Updated:  1/5/2016
Novartis Investigative Site
mi
from
Gainesville, FL
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
Status: Enrolling
Updated: 1/5/2016
Novartis Investigative Site
mi
from
Gainesville, FL
Click here to add this to my saved trials
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
Status: Enrolling
Updated:  1/5/2016
Novartis Investigative Site
mi
from
Honolulu, HI
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
Status: Enrolling
Updated: 1/5/2016
Novartis Investigative Site
mi
from
Honolulu, HI
Click here to add this to my saved trials
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
Status: Enrolling
Updated:  1/5/2016
Novartis Investigative Site
mi
from
Louisville, KY
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
Status: Enrolling
Updated: 1/5/2016
Novartis Investigative Site
mi
from
Louisville, KY
Click here to add this to my saved trials
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
Status: Enrolling
Updated:  1/5/2016
Novartis Investigative Site
mi
from
Tupelo, MS
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
Status: Enrolling
Updated: 1/5/2016
Novartis Investigative Site
mi
from
Tupelo, MS
Click here to add this to my saved trials
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
Status: Enrolling
Updated:  1/5/2016
Novartis Investigative Site
mi
from
Houston, TX
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
Status: Enrolling
Updated: 1/5/2016
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
Status: Enrolling
Updated:  1/5/2016
Novartis Investigative Site
mi
from
Richmond, VA
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
Status: Enrolling
Updated: 1/5/2016
Novartis Investigative Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
Status: Enrolling
Updated:  1/5/2016
Novartis Investigative Site
mi
from
Miami, FL
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
Status: Enrolling
Updated: 1/5/2016
Novartis Investigative Site
mi
from
Miami, FL
Click here to add this to my saved trials
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
Status: Enrolling
Updated:  1/5/2016
Novartis Investigative Site
mi
from
Tamarac, FL
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
Status: Enrolling
Updated: 1/5/2016
Novartis Investigative Site
mi
from
Tamarac, FL
Click here to add this to my saved trials
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
Status: Enrolling
Updated:  1/5/2016
Novartis Investigative Site
mi
from
Plano, TX
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease
Status: Enrolling
Updated: 1/5/2016
Novartis Investigative Site
mi
from
Plano, TX
Click here to add this to my saved trials
Dose of Labeled Cholesterol for Kinetics: A Pilot Study
Dose of Labeled Cholesterol and Phenylalanine for HDL Kinetics: A Pilot Study
Status: Enrolling
Updated:  1/5/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Dose of Labeled Cholesterol for Kinetics: A Pilot Study
Dose of Labeled Cholesterol and Phenylalanine for HDL Kinetics: A Pilot Study
Status: Enrolling
Updated: 1/5/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated:  1/5/2016
Ironwood Investigational Site
mi
from
Birmingham, AL
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated: 1/5/2016
Ironwood Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated:  1/5/2016
Ironwood Investigational Site
mi
from
Dothan, AL
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated: 1/5/2016
Ironwood Investigational Site
mi
from
Dothan, AL
Click here to add this to my saved trials
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated:  1/5/2016
Ironwood Investigational Site
mi
from
Tucson, AZ
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated: 1/5/2016
Ironwood Investigational Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated:  1/5/2016
Ironwood Investigational Site
mi
from
North Little Rock, AR
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated: 1/5/2016
Ironwood Investigational Site
mi
from
North Little Rock, AR
Click here to add this to my saved trials
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated:  1/5/2016
Ironwood Investigational Site
mi
from
Chula Vista, CA
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated: 1/5/2016
Ironwood Investigational Site
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated:  1/5/2016
Ironwood Investigational Site
mi
from
Los Angeles, CA
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated: 1/5/2016
Ironwood Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated:  1/5/2016
Ironwood Investigational Site
mi
from
Ventura, CA
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated: 1/5/2016
Ironwood Investigational Site
mi
from
Ventura, CA
Click here to add this to my saved trials
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated:  1/5/2016
Ironwood Investigational Site
mi
from
Miami, FL
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated: 1/5/2016
Ironwood Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated:  1/5/2016
Ironwood Investigational Site
mi
from
Tampa, FL
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated: 1/5/2016
Ironwood Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated:  1/5/2016
Ironwood Investigational Site
mi
from
Urbana, IL
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated: 1/5/2016
Ironwood Investigational Site
mi
from
Urbana, IL
Click here to add this to my saved trials
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated:  1/5/2016
Ironwood Investigational Site
mi
from
Bastrop, LA
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated: 1/5/2016
Ironwood Investigational Site
mi
from
Bastrop, LA
Click here to add this to my saved trials
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated:  1/5/2016
Ironwood Investigational Site
mi
from
Chesterfield, MI
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis
Status: Enrolling
Updated: 1/5/2016
Ironwood Investigational Site
mi
from
Chesterfield, MI
Click here to add this to my saved trials